{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T03:16:46Z","timestamp":1771643806507,"version":"3.50.1"},"reference-count":126,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.phrs.2014.02.003","type":"journal-article","created":{"date-parts":[[2014,2,15]],"date-time":"2014-02-15T18:31:11Z","timestamp":1392489071000},"page":"20-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Clinical evidence of statin therapy in non-dyslipidemic disorders"],"prefix":"10.1016","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8898-7441","authenticated-orcid":false,"given":"Nicola","family":"Ferri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Corsini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2014.02.003_bib0005","first-page":"892","article-title":"Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12e","volume":"31","author":"Bersot","year":"2011","journal-title":"Drug Therapy for Hypercholesterolemia and Dyslipidemia"},{"key":"10.1016\/j.phrs.2014.02.003_bib0010","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2014.02.003_bib0015","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"issue":"Suppl. 2","key":"10.1016\/j.phrs.2014.02.003_bib0020","first-page":"B72","article-title":"Pleiotropic effects of statins in atherosclerosis and diabetes","volume":"23","author":"Bellosta","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.phrs.2014.02.003_bib0025","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.jacc.2013.04.066","article-title":"Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography\/computed tomography feasibility study","volume":"62","author":"Tawakol","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.phrs.2014.02.003_bib0030","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(09)60447-5","article-title":"Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial","volume":"373","author":"Ridker","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2014.02.003_bib0035","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1161\/ATVBAHA.107.139881","article-title":"Simvastatin reduces MMP1 expression in human smooth muscle cells cultured on polymerized collagen by inhibiting Rac1 activation","volume":"27","author":"Ferri","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"Pt 2","key":"10.1016\/j.phrs.2014.02.003_bib0040","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1042\/0264-6021:3480241","article-title":"Rho GTPases and their effector proteins","volume":"348","author":"Bishopand","year":"2000","journal-title":"Biochem J"},{"key":"10.1016\/j.phrs.2014.02.003_bib0045","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/nature01148","article-title":"Rho GTPases in cell biology","volume":"420","author":"Etienne-Mannevilleand","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2014.02.003_bib0050","first-page":"611","article-title":"Are pleiotropic effects of statins real?","volume":"3","author":"Corsini","year":"2007","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.phrs.2014.02.003_bib0055","doi-asserted-by":"crossref","first-page":"5408","DOI":"10.1016\/j.bmcl.2011.07.003","article-title":"Thiazole- and imidazole-containing peptidomimetic inhibitors of protein farnesyltransferase","volume":"21","author":"Bolchi","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.phrs.2014.02.003_bib0060","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3109\/07853890008998823","article-title":"Non-lipid-related effects of statins","volume":"32","author":"Bellosta","year":"2000","journal-title":"Ann Med"},{"key":"10.1016\/j.phrs.2014.02.003_bib0065","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1124\/pr.111.004994","article-title":"Pharmacological actions of statins: a critical appraisal in the management of cancer","volume":"64","author":"Gazzerro","year":"2012","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.phrs.2014.02.003_bib0070","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/art.21521","article-title":"Statins as antiinflammatory and immunomodulatory agents: a future in rheumatologic therapy?","volume":"54","author":"Abelesand","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.phrs.2014.02.003_bib0075","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/1529-0131(200112)44:12<2737::AID-ART460>3.0.CO;2-#","article-title":"High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors","volume":"44","author":"del Rincon","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.phrs.2014.02.003_bib0080","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1161\/01.CIR.0000054612.26458.B2","article-title":"Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis","volume":"107","author":"Solomon","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2014.02.003_bib0085","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S0140-6736(03)12901-7","article-title":"New evidence for vascular disease in patients with early rheumatoid arthritis","volume":"361","author":"Kaplanand","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2014.02.003_bib0090","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1056\/NEJM195310012491402","article-title":"Length of life and cause of death in rheumatoid arthritis","volume":"249","author":"Cobb","year":"1953","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2014.02.003_bib0095","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/art.22600","article-title":"Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis","volume":"56","author":"Schneeweiss","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.phrs.2014.02.003_bib0100","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1161\/01.CIR.100.21.2124","article-title":"A tale of two diseases: atherosclerosis and rheumatoid arthritis","volume":"100","author":"Pasceriand","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2014.02.003_bib0105","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/art.24092","article-title":"Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies","volume":"59","author":"Avina-Zubieta","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.phrs.2014.02.003_bib0110","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/ard.2009.113696","article-title":"EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis","volume":"69","author":"Peters","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.phrs.2014.02.003_bib0115","first-page":"62","article-title":"Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis","volume":"29","author":"Turesson","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.phrs.2014.02.003_bib0120","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1136\/ard.2009.115717","article-title":"Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk?","volume":"69","author":"Toms","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.phrs.2014.02.003_bib0125","first-page":"S877","article-title":"Compliance with statin therapy in rheumatoid arthritis in patients","volume":"59","author":"Goyochea-Robles","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.phrs.2014.02.003_bib0130","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/ard.2010.142455","article-title":"Statin discontinuation and risk of acute myocardial infarction in patients with rheumatoid arthritis: a population-based cohort study","volume":"70","author":"De Vera","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.phrs.2014.02.003_bib0135","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/acr.21643","article-title":"Impact of statin discontinuation on mortality in patients with rheumatoid arthritis: a population-based study","volume":"64","author":"De Vera","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.phrs.2014.02.003_bib0140","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1136\/ard.2010.135871","article-title":"Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease","volume":"70","author":"Myasoedova","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.phrs.2014.02.003_bib0145","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3899\/jrheum.110318","article-title":"Effectiveness of statins on total cholesterol and cardiovascular disease and all-cause mortality in osteoarthritis and rheumatoid arthritis","volume":"39","author":"Sheng","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.phrs.2014.02.003_bib0150","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1002\/acr.22029","article-title":"The impact of statin use on lipid levels in statin-naive patients with rheumatoid arthritis (RA) vs. non-RA subjects: results from a population-based study","volume":"65","author":"Myasoedova","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.phrs.2014.02.003_bib0155","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/rheumatology\/keq295","article-title":"Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial","volume":"50","author":"Semb","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.phrs.2014.02.003_bib0160","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1002\/art.34524","article-title":"Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease","volume":"64","author":"Semb","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.phrs.2014.02.003_bib0165","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(04)16449-0","article-title":"Trial of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomised placebo-controlled trial","volume":"363","author":"McCarey","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2014.02.003_bib0170","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1136\/annrheumdis-2011-200806","article-title":"Initiation and adherence to secondary prevention pharmacotherapy after myocardial infarction in patients with rheumatoid arthritis: a nationwide cohort study","volume":"71","author":"Lindhardsen","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.phrs.2014.02.003_bib0175","unstructured":"TRACE-RA [accessed 02.09.13]."},{"key":"10.1016\/j.phrs.2014.02.003_bib0180","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1194\/jlr.M010876","article-title":"Atorvastatin upregulates regulatory T cells and reduces clinical disease activity in patients with rheumatoid arthritis","volume":"52","author":"Tang","year":"2011","journal-title":"J Lipid Res"},{"key":"10.1016\/j.phrs.2014.02.003_bib0185","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1002\/eji.200636567","article-title":"Simvastatin inhibits the MHC class II pathway of antigen presentation by impairing Ras superfamily GTPases","volume":"36","author":"Ghittoni","year":"2006","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.phrs.2014.02.003_bib0190","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1084\/jem.20051129","article-title":"Isoprenoids determine Th1\/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin","volume":"203","author":"Dunn","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.phrs.2014.02.003_bib0195","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.4049\/jimmunol.170.3.1524","article-title":"A novel anti-inflammatory role for simvastatin in inflammatory arthritis","volume":"170","author":"Leung","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.phrs.2014.02.003_bib0200","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00296-006-0270-9","article-title":"Effects of pravastatin in murine collagen-induced arthritis","volume":"27","author":"Yamagata","year":"2007","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.phrs.2014.02.003_bib0205","first-page":"964","article-title":"Beneficial action of statins in patients with rheumatoid arthritis in a large observational cohort","volume":"34","author":"Okamoto","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.phrs.2014.02.003_bib0210","first-page":"2024","article-title":"Antiinflammatory effect of simvastatin in patients with rheumatoid arthritis","volume":"29","author":"Kanda","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.phrs.2014.02.003_bib0215","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3109\/s10165-009-0261-2","article-title":"A comparative study of anti-inflammatory and antidyslipidemic effects of fenofibrate and statins on rheumatoid arthritis","volume":"20","author":"Goto","year":"2010","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.phrs.2014.02.003_bib0220","first-page":"326258","article-title":"The role of simvastatin in the therapeutic approach of rheumatoid arthritis","volume":"2013","author":"Cojocaru","year":"2013","journal-title":"Autoimmune Dis"},{"key":"10.1016\/j.phrs.2014.02.003_bib0225","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1365-2125.2009.03560.x","article-title":"Is there an anti-inflammatory effect of statins in rheumatoid arthritis? Analysis of a large routinely collected claims database","volume":"69","author":"Lodi","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.phrs.2014.02.003_bib0230","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1136\/ard.2010.136093","article-title":"Statins inhibit the antirheumatic effects of rituximab in rheumatoid arthritis: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry","volume":"70","author":"Arts","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.phrs.2014.02.003_bib0235","doi-asserted-by":"crossref","first-page":"e1000336","DOI":"10.1371\/journal.pmed.1000336","article-title":"Persistence with statins and onset of rheumatoid arthritis: a population-based cohort study","volume":"7","author":"Chodick","year":"2010","journal-title":"PLoS Med"},{"key":"10.1016\/j.phrs.2014.02.003_bib0240","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1136\/ard.2008.091967","article-title":"Hyperlipidaemia, statin use and the risk of developing rheumatoid arthritis","volume":"68","author":"Jick","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.phrs.2014.02.003_bib0245","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/art.20541","article-title":"Treatment with statins does not exhibit a clinically relevant corticosteroid-sparing effect in patients with giant cell arteritis","volume":"51","author":"Garcia-Martinez","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.phrs.2014.02.003_bib0250","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0140-6736(06)68041-0","article-title":"Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis","volume":"367","author":"Hackam","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2014.02.003_bib0255","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1056\/NEJMc051738","article-title":"Statins and the risk of colorectal cancer","volume":"353","author":"Setoguchi","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2014.02.003_bib0260","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1111\/j.1538-7836.2006.02058.x","article-title":"Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis","volume":"4","author":"Prandoni","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.phrs.2014.02.003_bib0265","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1161\/01.ATV.17.2.265","article-title":"Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis","volume":"17","author":"Colli","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.phrs.2014.02.003_bib0270","doi-asserted-by":"crossref","first-page":"397","DOI":"10.5414\/CPP41397","article-title":"Statins differ in their ability to block NF-kappaB activation in human blood monocytes","volume":"41","author":"Hilgendorff","year":"2003","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.phrs.2014.02.003_bib0275","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1161\/01.ATV.0000012802.69414.A8","article-title":"Fluvastatin reduces tissue factor expression and macrophage accumulation in carotid lesions of cholesterol-fed rabbits in the absence of lipid lowering","volume":"22","author":"Baetta","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.phrs.2014.02.003_bib0280","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0021-9150(02)00387-8","article-title":"Simvastatin inhibits expression of tissue factor in advanced atherosclerotic lesions of apolipoprotein E deficient mice independently of lipid lowering: potential role of simvastatin-mediated inhibition of Egr-1 expression and activation","volume":"167","author":"Bea","year":"2003","journal-title":"Arteriosclerosis"},{"key":"10.1016\/j.phrs.2014.02.003_bib0285","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.phrs.2007.02.001","article-title":"Rosuvastatin displays anti-atherothrombotic and anti-inflammatory properties in apoE-deficient mice","volume":"55","author":"Monetti","year":"2007","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.phrs.2014.02.003_bib0290","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1160\/TH05-01-0067","article-title":"Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia","volume":"94","author":"Undas","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.phrs.2014.02.003_bib0295","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/S0735-1097(99)00023-6","article-title":"Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia","volume":"33","author":"Szczeklik","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.phrs.2014.02.003_bib0300","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1001\/archinte.161.11.1405","article-title":"Use of statins and the subsequent development of deep vein thrombosis","volume":"161","author":"Ray","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.phrs.2014.02.003_bib0305","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1538-7836.2008.03235.x","article-title":"HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis","volume":"7","author":"Ramcharan","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.phrs.2014.02.003_bib0310","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1161\/01.CIR.0000019406.74017.B2","article-title":"Statin therapy, cardiovascular events, and total mortality in the heart and estrogen\/progestin replacement study (HERS)","volume":"105","author":"Herrington","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2014.02.003_bib0315","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1538-7836.2009.03279.x","article-title":"Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population-based case\u2013control study","volume":"7","author":"Sorensen","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.phrs.2014.02.003_bib0320","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.thromres.2007.10.014","article-title":"Differential associations between lipid-lowering drugs, statins and fibrates, and venous thromboembolism: role of drug induced homocysteinemia?","volume":"122","author":"Lacut","year":"2008","journal-title":"Thromb Res"},{"key":"10.1016\/j.phrs.2014.02.003_bib0325","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.thromres.2010.12.020","article-title":"Statin use in patients with nephrotic syndrome is associated with a lower risk of venous thromboembolism","volume":"127","author":"Resh","year":"2011","journal-title":"Thromb Res"},{"key":"10.1016\/j.phrs.2014.02.003_bib0330","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1365-2125.2008.03308.x","article-title":"Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials","volume":"67","author":"Smeeth","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.phrs.2014.02.003_bib0335","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1046\/j.0306-5251.2001.01523.x","article-title":"Statins and the risk of idiopathic venous thromboembolism","volume":"53","author":"Yang","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.phrs.2014.02.003_bib0340","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.thromres.2011.05.012","article-title":"Statins in the prevention of venous thromboembolism: a meta-analysis of observational studies","volume":"128","author":"Pai","year":"2011","journal-title":"Thromb Res"},{"key":"10.1016\/j.phrs.2014.02.003_bib0345","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa0900241","article-title":"A randomized trial of rosuvastatin in the prevention of venous thromboembolism","volume":"360","author":"Glynn","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2014.02.003_bib0350","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1093\/eurheartj\/ehp556","article-title":"Statins, fibrates, and venous thromboembolism: a meta-analysis","volume":"31","author":"Squizzato","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.phrs.2014.02.003_bib0355","first-page":"CD008203","article-title":"Statins for primary prevention of venous thromboembolism","author":"Li","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.phrs.2014.02.003_bib0360","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1471-2318-11-8","article-title":"Incident venous thromboembolic events in the prospective study of pravastatin in the elderly at risk (PROSPER)","volume":"11","author":"Freeman","year":"2011","journal-title":"BMC Geriatr"},{"key":"10.1016\/j.phrs.2014.02.003_bib0365","doi-asserted-by":"crossref","first-page":"e1001310","DOI":"10.1371\/journal.pmed.1001310","article-title":"Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials","volume":"9","author":"Rahimi","year":"2012","journal-title":"PLoS Med"},{"key":"10.1016\/j.phrs.2014.02.003_bib0370","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group","volume":"339","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2014.02.003_bib0375","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa061894","article-title":"Prevention by aggressive reduction in cholesterol levels. High-dose atorvastatin after stroke or transient ischemic attack","volume":"355","author":"Amarenco","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2014.02.003_bib0380","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2014.02.003_bib0385","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1111\/j.1523-1755.2004.00919.x","article-title":"Effect of fluvastatin on renal end points in the assessment of lescol in renal transplant (ALERT) trial","volume":"66","author":"Fellstrom","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.phrs.2014.02.003_bib0390","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2014.02.003_bib0395","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure","volume":"357","author":"Kjekshus","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2014.02.003_bib0400","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2014.02.003_bib0405","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1136\/heartjnl-2012-302906","article-title":"Adherence to statins is associated with reduced incidence of idiopathic venous thromboembolism: real-life data from a large healthcare maintenance organisation","volume":"98","author":"Rabinowich","year":"2012","journal-title":"Heart"},{"key":"10.1016\/j.phrs.2014.02.003_bib0410","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1136\/bmj.39024.513218.BE","article-title":"The lesser known effects of statins: benefits on infectious outcomes may be explained by \u201chealthy user\u201d effect","volume":"333","author":"Thomsen","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.phrs.2014.02.003_bib0415","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0025-6196(24)00530-5","article-title":"Noanalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease","volume":"55","author":"Ludwig","year":"1980","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.phrs.2014.02.003_bib0420","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/gast.2002.34168","article-title":"Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma","volume":"123","author":"Bugianesi","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2014.02.003_bib0425","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/hep.23314","article-title":"Decreased survival of subjects with elevated liver function tests during a 28-year follow-up","volume":"51","author":"Soderberg","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.phrs.2014.02.003_bib0430","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1007\/s10620-011-1767-y","article-title":"Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease","volume":"56","author":"Nseir","year":"2011","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.phrs.2014.02.003_bib0435","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s11936-009-0028-2","article-title":"Use of statins in patients with liver disease","volume":"11","author":"Tandraand","year":"2009","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"10.1016\/j.phrs.2014.02.003_bib0440","doi-asserted-by":"crossref","first-page":"77C","DOI":"10.1016\/j.amjcard.2005.12.014","article-title":"An assessment of statin safety by hepatologists","volume":"97","author":"Cohen","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.phrs.2014.02.003_bib0445","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1097\/MCG.0b013e31819c392e","article-title":"A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial","volume":"43","author":"Nelson","year":"2009","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.phrs.2014.02.003_bib0450","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/S0140-6736(10)61272-X","article-title":"Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek atorvastatin and coronary heart disease evaluation (GREACE) study: a post-hoc analysis","volume":"376","author":"Athyros","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2014.02.003_bib0455","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/ajg.2010.299","article-title":"Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial","volume":"106","author":"Foster","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.phrs.2014.02.003_bib0460","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1365-2796.2010.02305.x","article-title":"Effects of high-dose statin on the human hepatic expression of genes involved in carbohydrate and triglyceride metabolism","volume":"269","author":"Pramfalk","year":"2011","journal-title":"J Intern Med"},{"key":"10.1016\/j.phrs.2014.02.003_bib0465","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/archopht.125.4.534","article-title":"Subclinical atherosclerotic cardiovascular disease and early age-related macular degeneration in a multiracial cohort: the Multiethnic Study of Atherosclerosis","volume":"125","author":"Klein","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.phrs.2014.02.003_bib0470","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1001\/archopht.119.10.1455","article-title":"Risk factors for age-related maculopathy: the visual impairment project","volume":"119","author":"McCarty","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.phrs.2014.02.003_bib0475","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/S0161-6420(95)30846-9","article-title":"Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study","volume":"102","author":"Mitchell","year":"1995","journal-title":"Ophthalmology"},{"key":"10.1016\/j.phrs.2014.02.003_bib0480","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/S0161-6420(00)00175-5","article-title":"The prevalence of age-related maculopathy: the visual impairment project","volume":"107","author":"Van Newkirk","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/j.phrs.2014.02.003_bib0485","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1001\/archopht.119.12.1833","article-title":"Relationship of dietary fat to age-related maculopathy in the Third National Health and Nutrition Examination Survey","volume":"119","author":"Heuberger","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.phrs.2014.02.003_bib0490","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/archopht.1995.01100060069034","article-title":"Dietary fat and age-related maculopathy","volume":"113","author":"Mares-Perlman","year":"1995","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.phrs.2014.02.003_bib0495","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1001\/archopht.119.8.1191","article-title":"Dietary fat and risk for advanced age-related macular degeneration","volume":"119","author":"Seddon","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.phrs.2014.02.003_bib0500","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1001\/archopht.1992.01080240041025","article-title":"Risk factors for neovascular age-related macular degeneration. The Eye Disease Case\u2013Control Study Group","volume":"110","year":"1992","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.phrs.2014.02.003_bib0505","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1001\/archopht.121.8.1151","article-title":"Relation of statin use to the 5-year incidence and progression of age-related maculopathy","volume":"121","author":"Klein","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.phrs.2014.02.003_bib0510","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1001\/archopht.119.9.1354","article-title":"Medication use and the 5-year incidence of early age-related maculopathy: the Beaver Dam Eye study","volume":"119","author":"Klein","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.phrs.2014.02.003_bib0515","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1076\/opep.8.4.237.1613","article-title":"Associations of cardiovascular disease and its risk factors with age-related macular degeneration: the POLA study","volume":"8","author":"Delcourt","year":"2001","journal-title":"Ophthal Epidemiol"},{"key":"10.1016\/j.phrs.2014.02.003_bib0520","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1136\/bmj.326.7383.255","article-title":"Cholesterol lowering drugs and risk of age related maculopathy: prospective cohort study with cumulative exposure measurement","volume":"326","author":"van Leeuwen","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.phrs.2014.02.003_bib0525","doi-asserted-by":"crossref","first-page":"340","DOI":"10.5694\/j.1326-5377.2001.tb143604.x","article-title":"Cholesterol-lowering medications reduce the risk of age-related maculopathy progression","volume":"175","author":"McCarty","year":"2001","journal-title":"Med J Aust"},{"key":"10.1016\/j.phrs.2014.02.003_bib0530","first-page":"1121","article-title":"Evaluation of the retinal effects of simvastatin in patients with agerelated macular degeneration","volume":"117","author":"Martini","year":"1991","journal-title":"Annali Di Ottalmologia e Clinica Oculistica"},{"key":"10.1016\/j.phrs.2014.02.003_bib0535","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2147\/CIA.S2748","article-title":"Can HMG Co-A reductase inhibitors (\u201cstatins\u201d) slow the progression of age-related macular degeneration? The age-related maculopathy statin study (ARMSS)","volume":"3","author":"Guymer","year":"2008","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.phrs.2014.02.003_bib0540","doi-asserted-by":"crossref","first-page":"e418","DOI":"10.1111\/aos.12114","article-title":"Effect of simvastatin on retinal vascular caliber: the age-related maculopathy statin study","volume":"91","author":"Sasaki","year":"2013","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.phrs.2014.02.003_bib0545","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1056\/NEJMra041536","article-title":"Polycystic ovary syndrome","volume":"352","author":"Ehrmann","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2014.02.003_bib0550","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1210\/jc.2003-032046","article-title":"The prevalence and features of the polycystic ovary syndrome in an unselected population","volume":"89","author":"Azziz","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.phrs.2014.02.003_bib0555","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1093\/humrep\/des463","article-title":"Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp","volume":"28","author":"Stepto","year":"2013","journal-title":"Hum Reprod"},{"key":"10.1016\/j.phrs.2014.02.003_bib0560","doi-asserted-by":"crossref","first-page":"4237","DOI":"10.1210\/jc.2006-0178","article-title":"Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline","volume":"91","author":"Azziz","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.phrs.2014.02.003_bib0565","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1210\/jc.2005-2430","article-title":"Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome","volume":"91","author":"Lo","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.phrs.2014.02.003_bib0570","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1053\/meta.2000.7716a","article-title":"Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia","volume":"49","author":"Dobs","year":"2000","journal-title":"Metabolism"},{"key":"10.1016\/j.phrs.2014.02.003_bib0575","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1055\/s-0032-1304619","article-title":"Statin is a reasonable treatment option for patients with polycystic ovary syndrome: a meta-analysis of randomized controlled trials","volume":"120","author":"Gao","year":"2012","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.phrs.2014.02.003_bib0580","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1210\/jc.2008-1750","article-title":"The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study","volume":"94","author":"Sathyapalan","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.phrs.2014.02.003_bib0585","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1258\/acb.2011.011071","article-title":"Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study","volume":"49","author":"Sathyapalan","year":"2012","journal-title":"Ann Clin Biochem"},{"key":"10.1016\/j.phrs.2014.02.003_bib0590","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1210\/jc.2006-1988","article-title":"Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial","volume":"92","author":"Banaszewska","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.phrs.2014.02.003_bib0595","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1210\/jc.2009-1674","article-title":"Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial","volume":"94","author":"Banaszewska","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.phrs.2014.02.003_bib0600","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1210\/jc.2011-0501","article-title":"Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment","volume":"96","author":"Banaszewska","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.phrs.2014.02.003_bib0605","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.fertnstert.2008.06.006","article-title":"Comparative effects of atorvastatin and simvastatin on the plasma total homocysteine levels in women with polycystic ovary syndrome: a prospective randomized study","volume":"92","author":"Kaya","year":"2009","journal-title":"Fertil Steril"},{"key":"10.1016\/j.phrs.2014.02.003_bib0610","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1191\/0961203303lu429oa","article-title":"Therapy with statins in patients with refractory rheumatic diseases: a preliminary study","volume":"12","author":"Abud-Mendoza","year":"2003","journal-title":"Lupus"},{"key":"10.1016\/j.phrs.2014.02.003_bib0615","first-page":"2095","article-title":"Effects of angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with longterm rheumatoid arthritis","volume":"32","author":"Tikiz","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.phrs.2014.02.003_bib0620","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.jacc.2007.04.076","article-title":"Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis","volume":"50","author":"Maki-Petaja","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.phrs.2014.02.003_bib0625","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2014.02.003_bib0630","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1016\/j.fertnstert.2009.11.045","article-title":"Effects of metformin plus simvastatin on polycystic ovary syndrome: a prospective, randomized, double-blind, placebo-controlled study","volume":"94","author":"Kazerooni","year":"2010","journal-title":"Fertil Steril"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661814000164?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661814000164?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T21:28:34Z","timestamp":1746134914000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661814000164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":126,"alternative-id":["S1043661814000164"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2014.02.003","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical evidence of statin therapy in non-dyslipidemic disorders","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2014.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}